Nov 3 (Reuters) - Immunovaccine Inc IMV.TO
* Neoepitope peptides formulated in immunovaccine's depovax(tm) vaccine platform show significant positive results in preclinical studies Source text for Eikon: ID:nMKWFqxJna Further company coverage: IMV.TO